International Myeloma Working Group recommendations for global myeloma care.
about
The Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in ChinaTreatment of relapsed and refractory multiple myelomaMature B cell neoplasms: retrospective analysis of 93 cases diagnosed between 2011 and 2014 in a University Hospital in southern BrazilMaintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaNovel therapeutic targets in myeloma bone disease.Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple MyelomaDilemmas in treating smoldering multiple myeloma.Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies.Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplaDiagnostic and therapeutic approaches to multiple myeloma patients: 'Real-world' data from representative multicentre treatment surveys in Germany between 2008 and 2011.Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myelomaThe Diagnosis and Treatment of Multiple MyelomaLong-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone.Nucleotide excision repair is a potential therapeutic target in multiple myeloma.Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.Treatment of Newly Diagnosed Elderly Multiple Myeloma.Multiple myeloma: practice patterns across Europe.Efficacy and safety of elotuzumab for the treatment of multiple myeloma.Emerging treatment approaches for myeloma-related bone disease.The possible role of burden of therapy on the risk of myeloma extramedullary spread.Safety of ixazomib for the treatment of multiple myeloma.Comparison of Fully Automated and Semiautomated Systems for Protein Immunofixation Electrophoresis.Prediction of patients with multiple myeloma eligible for second- or third-line treatment in France.Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma.The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea.Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance.Light Chain Escape in 3 Cases: Evidence of Intraclonal Heterogeneity in Multiple Myeloma from a Single Institution in Poland.RAS mutation status and bortezomib therapy for relapsed multiple myeloma.Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.Serum free light chain quantitative assays: Dilemma of a biomarker.'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma.Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.
P2860
Q26740446-FF74609F-79E5-4ACB-8B45-E5B245BEF75AQ26749180-9260EB71-9413-46D5-8B8A-FB9339B62449Q28395001-2CB3DA22-B403-4479-8958-E912C8B802B7Q30275382-9FD082EE-CEB2-468B-9744-DF1EB8E98505Q30276010-4B850C9E-9CE7-4DBA-B23D-5B5435A41916Q30313340-1552F3DE-9C17-44D9-A95E-504B55C40ACBQ31154933-4CE8F4F4-E288-4FBA-BEBA-443AC5429C28Q33413142-53946E1D-D57D-484D-B66F-2D4AF43F58CFQ34025065-1B494CBE-4447-4AE7-B43F-4158631278F4Q34345502-97277A36-23A9-47CB-A35B-12CEB71BDAB6Q34694749-276E8D39-6FC5-4BAC-99C0-E52E29CC510FQ34716500-4F9F24BC-F0B7-4C74-8F46-6D4D7B5F49AAQ35669893-C5BC6795-8957-43DB-A4FC-120E818DBA5DQ35830856-E7B400B3-7C46-465C-9230-06BD7E5CB3D4Q35999062-8D02E4F8-8054-462D-B440-1F7E5EE8C15CQ36254820-632FFE38-5E04-4070-8B48-B9FA89F9031EQ36750472-CF8B8B83-237C-4F04-8ECE-C8C86063D1DFQ37150733-DDD0ABB3-1278-4C7A-8218-7100E269B834Q38713479-89EBFC75-B52B-4DF4-833F-36DB053A5D78Q38739689-6F277FD1-FEDF-439D-A8DF-D09132CFB8E5Q38749573-2EF54F46-A307-43B2-9468-6797D629D1BCQ38778519-80F6D0B9-D73A-49BD-AF9E-6E63D9B49082Q38815405-DB32EB28-8702-4F2B-BD44-72F1D959B8D1Q38862553-E1C2DA53-6B09-4167-B491-1FB1DB2FE0D4Q39070515-88018386-3F32-4C31-B722-5B045C5FFEE7Q39090721-67A2131B-C553-4015-A026-932944661207Q39264310-878BAD15-EAD2-4770-8A7B-0C1A476875D7Q39404809-2A4B7E82-8DD7-4EAB-8DAA-A0ADAB3F64E5Q39594256-B8310A6C-B32B-4C3E-8EE5-6B63DC2D4689Q39778109-35E8790E-6F84-4848-A979-18AB9808E77FQ40455903-9BD4C226-C368-4590-965D-A363CB21BAA7Q40813914-1CF9449B-728C-4747-889F-BBD6E9CE34C7Q41002965-6759789F-25F4-47B5-BE33-339C5512F562Q41810975-DF258766-9ECD-46D6-B7B6-A3FBB92F2EBFQ45066307-143182C1-7E91-435B-A8D1-29EAFD6B73F3Q47149240-4ECF5786-E7BE-4C82-B9FA-3DF9AE668756Q47324989-0BD9A866-A079-4920-940D-D05661431C4EQ48205014-A6C102DA-C7F5-47DC-B1D1-91629685B432Q48515598-439384AF-305D-4168-BB4C-357E6D032F4AQ50589659-FC1A2C3B-1B46-4181-B823-0073ADEA31F8
P2860
International Myeloma Working Group recommendations for global myeloma care.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
International Myeloma Working Group recommendations for global myeloma care.
@en
type
label
International Myeloma Working Group recommendations for global myeloma care.
@en
prefLabel
International Myeloma Working Group recommendations for global myeloma care.
@en
P2093
P2860
P50
P356
P1433
P1476
International Myeloma Working Group recommendations for global myeloma care.
@en
P2093
A Jurczyszyn
A Rodriguez Morales
D Ben-Yehuda
P2860
P2888
P304
P356
10.1038/LEU.2013.293
P577
2013-10-09T00:00:00Z
P6179
1013434190